GLP-1 Drugs Just Became the World's Best-Selling Drug Class (2026)

For about fifteen years, oncology owned the top spot. Cancer drugs collectively outsold every other therapeutic class — immunotherapy, cardiovascular, autoimmune, the whole aisle. That streak ended in Q1 2026. I keep rereading the sentence to make sure it's right: a drug class that didn't exist commercially when I was in college now outsells the entire cancer shelf.

Novo Nordisk and Eli Lilly reported first-quarter earnings within a week of each other, and the combined math is hard to miss: roughly $15.5 billion in GLP-1 revenue across the two companies in a single quarter. Annualized, that's about $62 billion — enough to leapfrog oncology's $58 billion run rate for the first time.

This wasn't a rounding error. GLP-1 agonists started as a niche diabetes treatment and turned into the most culturally visible pharmaceutical category since Viagra. As of this quarter, they're the highest-grossing drug class on the planet.

The Q1 2026 numbers, stripped down

A few line items are worth pulling out. Wegovy alone — Novo's obesity-indication semaglutide — hit roughly $2.8 billion in Q1. One brand, one quarter, more revenue than most biotech companies book in a year.

Zepbound, Lilly's tirzepatide for weight management, posted about $2.5 billion. It launched in late 2023, and it's been the fastest revenue ramp in pharmaceutical history. No other molecule has reached this run rate this fast. Not Lipitor. Not Humira. Not even close.

Then there's Foundayo. Lilly's oral GLP-1 (orforglipron) launched on April 1, 2026 at $149 a month — a price point built to blow open the access bottleneck. It doesn't register in the Q1 numbers at all: those close at the end of March, before the drug was even on sale, so there's no meaningful revenue line for it yet. But a $149 oral pill landing in a market where the injectables list north of $1,000 is the kind of entry that rearranges a category. Whether it converts into real volume is the open question of the back half of 2026.

How GLP-1s overtook cancer drugs

The crossover happened faster than anyone projected two years ago. In 2023, the combined GLP-1 market was around $35 billion. Oncology was somewhere north of $55 billion. The gap looked permanent.

Then the obesity indication broke open. Wegovy's FDA approval for weight management came in 2021. Zepbound followed in late 2023. And in August 2023, the SELECT cardiovascular outcomes trial reported — the moment the conversation flipped from "vanity drug" to "prevents heart attacks." Prescriptions for GLP-1s written for obesity, not diabetes, now make up about 40% of the total category volume in the US.

Oncology didn't shrink. It grew. But it grew at mid-single digits. GLP-1 revenue doubled between 2023 and 2025, and it's on pace to grow another 40–50% in 2026. Two curves moving at different speeds, and the faster one just crossed.

For context: the entire statin class at its peak — Lipitor, Crestor, all of them combined — generated roughly $35 billion a year. GLP-1s blew past that mark in 2025 and aren't decelerating.

Where the $15.5 billion per quarter goes

Record pharmaceutical revenue flows somewhere. For GLP-1s, the investment cycle is visible and specific.

Manufacturing. Novo Nordisk is spending $6 billion to expand its Kalundborg, Denmark production site — the largest semaglutide API facility on earth — with a goal of doubling capacity by 2027. Lilly has poured $5.3 billion into its Research Triangle Park (North Carolina) and Kenosha (Wisconsin) plants combined. The global semaglutide shortage that plagued 2022–2024 officially ended in February 2025, when FDA removed semaglutide from the shortage list. But fill-finish — the final step of getting drug into pens and vials — remains the bottleneck, not raw API production.

R&D pipeline. Both companies are funneling GLP-1 profits back into next-generation obesity drugs. Lilly's retatrutide (a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously) showed about 24% body weight loss in Phase 2, the highest figure any obesity drug has posted. CagriSema (Novo's semaglutide + cagrilintide combo), amycretin, and survodutide (Boehringer Ingelheim) are all in late-stage trials. The GLP-1 profits are funding the drugs that could eventually replace GLP-1s.

Price competition. Foundayo's $149 launch price didn't happen in a vacuum. Lilly set it to drag the whole market downward, and the pressure is working. Novo answered with the Hims partnership ($39 first month, then $79–$199 for branded access) and NovoCare's direct cash-pay channel. When a drug class throws off this much revenue, competitors and payers both gain leverage to push prices lower. It's already happening — slowly, awkwardly, with the kind of pricing announcements that read like apologies.

The US pricing picture, May 2026

The compounded-semaglutide market — the $99-to-$199 gray-market alternative that powered telehealth growth from 2022 to 2024 — is largely finished. FDA removed semaglutide from the shortage list in February 2025, the legal cover for mass compounding evaporated over the year, and the May 2026 enforcement posture has shut down most large-scale compounders. More on how the US access landscape shifted.

Two dates matter for pricing this year. July 1, 2026 is when the Medicare GLP-1 Bridge program opens: roughly 67 million Part D beneficiaries become eligible for Wegovy or Zepbound at a $50/month copay, assuming they meet clinical criteria (BMI 30+, or 27+ with comorbidity). And the Foundayo launch continues to put structural pressure on injection prices — when a $149 oral pill sits on the shelf next to a $1,349 injection, the injection's pricing power erodes whether or not the two molecules perform identically.

Market-by-market access snapshot

The $62 billion headline is mostly a US and European story — the US alone accounts for about 65% of it. But the drugs are approved in most major markets now, and what you pay swings wildly depending on where you live.

United States. An estimated 6 million+ patients are now on a GLP-1 for obesity, up from about 2 million in early 2024 — roughly a tripling in two years. Commercial insurance coverage is expanding but uneven. Medicare kicks in July 1.

South Korea. Wegovy (위고비) runs 210,000–370,000 KRW/month out of pocket; it's not covered by national health insurance for obesity. Mounjaro (마운자로) is similarly priced at 200,000–300,000 KRW/month. Crackdowns on overseas purchasing (해외직구) have intensified through 2025–2026.

Japan. Wegovy (ウゴービ) received PMDA approval in 2024. Self-pay through private clinics (自由診療) runs ¥30,000–80,000/month. Prescription volumes are climbing fast, but national health insurance doesn't cover obesity indication.

EU (Spain, France). Wegovy is available at roughly €300/month self-pay. Mounjaro launched across EU markets in 2024. French Sécurité sociale and Spanish national health don't reimburse for obesity. Germany has somewhat broader coverage through private Krankenkassen.

Saudi Arabia / UAE. SFDA and MOHAP have approved GLP-1s. Self-pay runs 1,200–2,000 SAR/month. Most insurance policies explicitly exclude obesity treatment.

China. NMPA approved Wegovy (诺和盈) in 2024, and Mounjaro (穆峰达) for type-2 diabetes in 2024 (with the weight-management indication following in 2025). Self-pay sits at ¥2,000–3,000/month. Cross-border purchasing crackdowns (代购) have escalated.

Taiwan. TFDA approved Wegovy (週纖達). Self-pay is NT$7,000–15,000/month. National health insurance (健保) excludes obesity.

Hong Kong. Private prescription only. Wegovy runs roughly HK$14,000–20,000/month at maintenance dose. VHIS voluntary health insurance doesn't cover it.

The pattern across all these markets is the same: regulatory approval is moving fast, insurance coverage for obesity is not. Revenue growth outside the US will hinge less on new approvals — most major markets already have at least one GLP-1 cleared for weight management — and more on whether payers start treating obesity like the chronic disease the WHO says it is. Decades of "lifestyle disease" framing doesn't unwind in a quarter.

Record sales, record counterfeits

Record sales create record incentives to fake the product. Interpol seized more than $600 million worth of counterfeit GLP-1 products across 2025–2026 — fake Ozempic pens, knockoff Wegovy packaging, semaglutide vials with no semaglutide in them, and worse, vials carrying unknown active ingredients.

The counterfeit risk tracks the price-access gap almost one to one. In a market where a month of Wegovy lists at $1,349 and insurance won't touch it, the pull toward a $200 "Ozempic" from an unverified source is enormous. As branded prices come down — Foundayo at $149, Hims at $79–$199 — some of that pull eases. But in places like Saudi Arabia, China, and parts of Latin America, where legitimate supply is expensive and local alternatives don't exist yet, the gray market is thriving.

If you're getting a GLP-1 from any channel you can't verify — no licensed pharmacy, no traceable lot number, no prescriber you can call — the risk calculus shifted in 2026. Legitimate options at $149 exist now. Full counterfeit safety guide.

The pipeline behind the revenue

What $62 billion in annual revenue buys is a pipeline that would have looked like science fiction five years ago. The next generation of obesity drugs is already in late-stage trials, funded by the profits from this one.

Retatrutide (Lilly). Triple agonist — GIP, GLP-1, glucagon. Phase 2 showed about 24% mean body weight loss at 48 weeks, the highest number any obesity drug candidate has posted. Phase 3 results expected late 2026 or early 2027.

CagriSema (Novo Nordisk). Semaglutide + cagrilintide in a single injection. Targeting 25%+ weight loss. Phase 3 ongoing. If it works as expected, it'll be Novo's answer to Lilly's dual- and triple-agonist pipeline.

Amycretin (Novo Nordisk). GLP-1 + amylin analog. Early data showed 13% weight loss in just 12 weeks — a speed that caught the field's attention. Still early, but the trajectory suggests a next-wave oral candidate.

Survodutide (Boehringer Ingelheim). Dual GLP-1/glucagon agonist. Targeting both obesity and MASH (metabolic dysfunction-associated steatohepatitis). Phase 3 in progress.

More detail on the full pipeline: Next-wave obesity drugs, 2026 update.

The competitive dynamic matters for patients. Every one of these pipeline drugs puts pricing pressure on the current market. Lilly didn't price Foundayo at $149 because it was feeling generous — it priced it there because oral convenience at a disruptive price point is how you defend share against the next entrant. When retatrutide launches, that same pressure intensifies.

What record revenue means if you're on one of these drugs

A $62 billion number doesn't move your copay by a dollar. But it reshapes the environment around your treatment in ways you can already feel.

Supply is improving. The 2022–2024 shortage — when Wegovy and Mounjaro were genuinely hard to fill — was a manufacturing capacity problem. Eleven billion dollars in combined factory investment from Novo and Lilly is solving it. The semaglutide shortage ended in early 2025. Tirzepatide supply stabilized earlier. If you had a prescription denied or delayed due to stock-outs in 2023 or 2024, the situation in 2026 is materially different.

Prices are falling, not rising. Wegovy's list price hasn't dropped, but net prices (after rebates) are declining, and the cash-pay channels — NovoCare, LillyDirect, Hims — have created a parallel pricing tier that didn't exist 18 months ago. Foundayo at $149 is the structural disruptor. Generic liraglutide at $250–$400 offers a lower-cost entry point with an older molecule.

Insurance coverage is expanding. The Medicare GLP-1 Bridge ($50/month starting July 1, 2026) covers 67 million beneficiaries. Employer-sponsored plans have been adding GLP-1 coverage through 2025 and 2026 at a steady clip. The political environment is shifting too — US Senate hearings on GLP-1 pricing ran in early 2026, and European access debates are intensifying.

More drugs are coming. The pipeline drugs above — retatrutide, CagriSema, amycretin, survodutide — all have Phase 3 data expected by early 2027. Each one that reaches market puts more downward pressure on what you pay.

In 2023, the problem was finding the drug — pharmacies couldn't keep Wegovy in stock. In 2024, it was affording it. By mid-2026, a $149 oral option exists, Medicare coverage starts in weeks, and cash-pay channels have cut the floor price in half. The access picture isn't solved, but it's unrecognizable from two years ago.

When the money gets political

Money at this scale draws political attention. GLP-1 pricing landed in front of the US Senate Finance Committee in February 2026, with both Novo Nordisk and Eli Lilly executives testifying on list-versus-net pricing and the role of PBMs in inflating costs. The hearings produced no legislation, but they set the framing for everything that follows: these drugs work, demand is enormous, and the pricing structure is hard to defend in public.

In Europe, the access fight is playing out on different terms. France's Haute Autorité de Santé is reviewing whether to add obesity-indication GLP-1s to the reimbursement list. Germany's GBA is doing the same. The UK's NHS has Wegovy on formulary but has struggled with uptake and supply since the 2023 rollout. The question across European markets is whether record global sales — and the manufacturing investment that follows — will finally resolve the supply constraints that have limited European access.

What to watch for the rest of 2026

Three inflection points between now and December.

July 1: Medicare GLP-1 Bridge launches. The single largest demand event in the category's history. If uptake is faster than CMS projected, it will stress supply chains and accelerate the political conversation about drug pricing. If it's slower, the story shifts to whether Part D formulary restrictions and prior-authorization requirements are functioning as intended or as barriers.

Q3 earnings (October). Novo and Lilly's Q2 and Q3 reports will show whether the Q1 pace holds. If GLP-1 revenue hits $17–18 billion combined in Q2, the annualized run rate pushes toward $70 billion. At that point, GLP-1s aren't just the top drug class — they're pulling away from oncology by a margin that redefines the industry.

Pipeline data. Retatrutide Phase 3 readouts, CagriSema topline results, and amycretin dose-finding updates are all expected in the second half of 2026. The data from these trials will determine whether the current two-company duopoly holds or opens up to a broader competitive field by 2028.

The GLP-1 category crossed $62 billion annualized for a simple reason: the drugs work, and the patient population is vast. The WHO estimates 890 million adults worldwide live with obesity, and fewer than 2% are currently treated pharmacologically. That's the part the revenue number doesn't capture. The $62 billion is already past tense. What matters next is whether all that manufacturing investment, insurance expansion, and pipeline competition turns into lower prices fast enough for the people doing the paying. Which, most mornings I open my inbox, still feels like the slowest math in the room.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. Sources are cited throughout; for the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app